Research programme: bone disorders and inflammatory disease therapeutics - Galapagos
Alternative Names: Bone and joint disorder therapeutics - Galapagos; GT146; GT328; GT442; Oral psoriasis therapy - Galapagos NV; Osteoporosis therapies - Galapagos; Rheumatoid arthritis therapies - GalapagosLatest Information Update: 28 Apr 2021
Price :
$50 *
At a glance
- Originator ProSkelia
- Developer Galapagos NV; Ghent University; Pfizer
- Class Antibodies; Small molecules
- Mechanism of Action Integrin inhibitors; Osteogenesis stimulants; Protein kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone disorders; Inflammation; Osteoporosis; Psoriasis
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Inflammation in Belgium
- 08 Apr 2019 The programme is still in preclinical phase for Inflammation in Belgium
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bone-disorders in Belgium